Fresh analysis indicates that individuals who come off popular GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight much more quickly than those who halt conventional lifestyle plans.
Published data in a prominent health publication points out that while obese people often shed a large proportion of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month once they quit.
"People buying such treatments need to be cognizant of the danger of quick weight regain when the treatment ends," stated expert Dr. Susan Jebb.
That rate of recovery means a return to original weight in about a year and a half.
Comparing Treatments
The analysis, which looked at dozens of studies involving thousands of participants, compared the outcomes of GLP-1 agonists with older methods.
The team note that people who lose weight through diet and exercise typically have a less rapid weight regain—around 0.1 kg a month—after stopping.
Explaining the Quick Regain
Experts propose the mechanism of the drugs explains the heightened rebound.
GLP-1 drugs copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Discontinuation of this medication means hunger is no longer kept in check, making overeating far more likely."
A Chronic Condition?
Medical guidelines suggest the injections for individuals with obesity-related medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, considering the high risk of relapse, the treatment should be considered ongoing.
This view is supported by drug manufacturers, who state that the findings "underscore the persistent character of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Users who have come off the jabs explain a intense resurgence of appetite.
"I experienced a trigger flipping and you're instantly ravenous," recalled a patient.
This difficulty is worsened if patients have not established permanent dietary or behavioural changes during therapy.
Widespread Interest
Recent estimates indicate that millions of people in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Use is more common among women compared to men.
- The 40s and 50s demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private healthcare rather than public health services.
Ultimately, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent solution and lasting health benefits relies on integrated behavioural support.
